Edition:
United States

ThromboGenics NV (THR.BR)

THR.BR on Brussels Stock Exchange

2.52EUR
9:39am EST
Change (% chg)

€0.00 (+0.04%)
Prev Close
€2.52
Open
€2.53
Day's High
€2.53
Day's Low
€2.50
Volume
55,803
Avg. Vol
16,383
52-wk High
€4.03
52-wk Low
€2.50

THR.BR

Chart for THR.BR

About

ThromboGenics NV is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. The Company’s lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was... (more)

Overall

Beta: 1.04
Market Cap(Mil.): €92.40
Shares Outstanding(Mil.): 36.09
Dividend: --
Yield (%): --

Financials

  THR.BR Industry Sector
P/E (TTM): -- 42.12 30.77
EPS (TTM): -0.94 -- --
ROI: -19.66 -0.81 15.23
ROE: -19.63 -1.52 16.56

BRIEF-Thrombogenics Q3 cash position at 88.2 million euros

* Q3 2016 cash position at 88.2 million euros ($96.42 million) Source text: http://bit.ly/2ebOCm3

Oct 20 2016

BRIEF-Thrombogenics H1 revenue down at 4.0 mln euros

* H1 revenue 4.0 million euros ($4.5 million) versus 6.0 million euros year ago

Aug 25 2016

BRIEF-Thrombogenics receives FDA approval for JETREA

* Receives US FDA approval for new 'already-diluted' formulation of JETREA

Jun 08 2016

Earnings vs. Estimates